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Better to know: the importance of early HIV diagnosis
Early diagnosis is key to successful treatment of HIV. 
Before the advent of highly active antiretroviral 
therapy (HAART) in 1996, HIV infection almost always 
resulted in a decline in immune function leading to 
opportunistic infections and early death from AIDS. The 
situation now is very diﬀ erent for people living with HIV 
who are on HAART. One pill a day can suppress the virus 
and near normal life expectancy is possible.1 However, 
this biomedical success story has many caveats. 
Findings of the START trial2 showed that morbidity 
and mortality is high when treatment is delayed. In 
recognition of this, the UK and other international HIV 
treatment guidelines recommend that ART be started 
immediately after diagnosis.
The study by Sara Croxford and colleagues3 reported 
in The Lancet Public Health documents mortality and 
causes of death in people diagnosed with HIV in the 
UK between 1997 and 2012. This study is important 
because it is based on national surveillance of people 
diagnosed with HIV who accessed care in the UK 
National Health Service (NHS). Previous studies in 
high-income countries reported mortality in the HIV 
positive population to be between 1·2 and 4·2 times 
higher than in the general population, but results were 
based on clinical cohorts of treated patients. Croxford 
and colleagues3 included people from diagnosis and 
therefore counted deaths in people who did not start 
treatment and noted nearly six times higher mortality 
in the HIV-positive population compared with the 
general UK population. The investigators explored two 
important explanations for this high mortality: the 
eﬀ ect of late diagnosis and the causes of death.
With regards to late diagnosis, until 2015 UK HIV 
treatment guidelines recommended that ART be 
started in HIV patients who had CD4 counts, a marker 
of immune function, lower than 350 cells per mm3. 
Therefore, late diagnosis was deﬁ ned as having a CD4 
count lower than 350 cells per mm3 within 3 months 
of diagnosis. During the study by Croxford and 
colleagues,3 61% of women and 51% of men were 
diagnosed late. Mortality was 24 times that of the UK 
population in the ﬁ rst year after diagnosis, dropping 
to 2·8 times thereafter.3 There is an urgent need 
to increase testing rates to reduce late diagnosis, 
especially in primary care settings where opportunities 
might be missed to detect primary infection as a 
ﬂ u-like illness or to screen for HIV when other blood 
tests are being done.4 General practitioners are advised 
to test for HIV if patients have an HIV indicator disease 
(a list of 39 disorders associated with HIV infection 
listed in the British HIV Association guidelines); 
however, barriers have been reported to implementing 
this guideline.5 High-risk individuals, such as men 
who have sex with men, are recommended to test 
frequently. Evidence suggests that proactive recall can 
increase re-testing rates for HIV in both heterosexuals 
and men who have sex with men attending clinics for 
sexually transmitted disease screening.6 Home testing 
using kits supplied via the internet might aﬀ ord more 
opportunities for early diagnosis.7 Research is needed 
to investigate ways of optimising linkage to care 
after a positive result. Among those who died in the 
reported study, nearly a quarter were not linked to 
HIV outpatient care, and a third of those who did link 
to care never received ART.3 Linkage to care is a crucial 
step in the cascade of care and needs to be made as 
easy as possible with good communication between 
place of diagnosis, which is often a sexual health clinic, 
and HIV clinic. Retention in care can be enhanced by 
reminders to attend clinic, adherence counselling, and 
addressing mental health, psychosexual and social care 
needs, as well as physical care.
Second, the causes of death shed light on the problems 
faced by people living with HIV. Perhaps unsurprisingly 
the major cause of death is still AIDS. Excess of deaths 
classiﬁ ed as non-AIDS infection likely reﬂ ects the 
imperfection of the list of AIDS deﬁ ning disorders; 
these bacterial infections thrive in people with immune 
deﬁ ciency and are directly HIV-related. Deaths due to 
suicide and overdose are potentially avoidable and 
suggest the need for improved mental health care, 
de-stigmatisation of HIV infection, and harm reduction 
programmes for those who use recreational drugs. 
Excess liver-related mortality in people who inject drugs 
(currently or historically) might be due to the recreational 
drugs themselves or alcohol, but in many cases is caused 
by co-infection with hepatitis C. Testing for hepatitis C and 
treatment with very eﬀ ective new direct acting antivirals 
should be standard of care for HIV-positive individuals to 
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In the UK, HIV care after diagnosis is provided for 
free and is excellent as assessed by Public Health 
England.8 Much progress has been made, with mortality 
in 2008–12 half that in 1998–2002,3 but further 
improvements in testing and prevention are needed to 
reduce undiagnosed infection, incidence, late diagnoses, 
and ultimately deaths due to HIV. The public health 
community must also be mindful that immigrant 
populations, especially those from countries where HIV 
is endemic, experience a disproportionate burden of HIV, 
delayed diagnosis, and poorer access to ART throughout 
Europe.9 Preventive measures targeting these vulnerable 
populations are important as a substantial proportion 
of HIV acquisition occurs after their arrival in Europe.10 
Ongoing monitoring of the public health response to 
national HIV epidemics using surveillance data from 
routinely collected laboratory and clinic data and linkage 
to death registries remains very important.11
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